CR20130199A - METHOD OF IDENTIFICATION OF RISK FACTORS OF THE DISEASE - Google Patents
METHOD OF IDENTIFICATION OF RISK FACTORS OF THE DISEASEInfo
- Publication number
- CR20130199A CR20130199A CR20130199A CR20130199A CR20130199A CR 20130199 A CR20130199 A CR 20130199A CR 20130199 A CR20130199 A CR 20130199A CR 20130199 A CR20130199 A CR 20130199A CR 20130199 A CR20130199 A CR 20130199A
- Authority
- CR
- Costa Rica
- Prior art keywords
- disease
- identification
- risk factors
- genetic
- variante
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000002068 genetic effect Effects 0.000 abstract 3
- 101000764216 Homo sapiens Mitochondrial import receptor subunit TOM40 homolog Proteins 0.000 abstract 1
- 102100026905 Mitochondrial import receptor subunit TOM40 homolog Human genes 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 230000008030 elimination Effects 0.000 abstract 1
- 238000003379 elimination reaction Methods 0.000 abstract 1
- 238000003780 insertion Methods 0.000 abstract 1
- 230000037431 insertion Effects 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
AQUI SE PROPORCIONA UN MÉTODO PARA LA IDENTIFICACIÓN DE UNA VARIANTE QUE ESTÁ ASOCIADA CON EL DESARROLLO DE UN PADECIMIENTO DE INTERÉS (POR EJEMPLO, LA ENFERMEDAD DE ALZHEIMER), Y LAS VARIANTES GENÉTICAS IDENTIFICADAS DE ESTA MANERA. TAMBIÉN SE PROPORCIONAN MÉTODOS DE TRATAMIENTO CON UN INGREDIENTE ACTIVO (POR EJEMPLO, CON UN AGENTE ACTIVO PARTICULAR Y / O EN UNA ETAPA MÁS TEMPARANA), AL MOMENTO DE DETECTAR UNA VARIANTE GENÉTICA AQUÍ DESCRITA. EN ALGUNAS MODALIDADES, LA VARIANTE GENÉTICA ES UN POLIMORFISMO DE ELIMINACIÓN / INSERCIÓN (DIP) DEL GEN TOMM40.-HERE IS PROVIDED A METHOD FOR THE IDENTIFICATION OF A VARIANTE THAT IS ASSOCIATED WITH THE DEVELOPMENT OF AN INTEREST OF INTEREST (FOR EXAMPLE, THE DISEASE OF ALZHEIMER), AND THE GENETIC VARIANTS IDENTIFIED IN THIS WAY. METHODS OF TREATMENT ARE ALSO PROVIDED WITH AN ACTIVE INGREDIENT (FOR EXAMPLE, WITH A PARTICULAR ACTIVE AGENT AND / OR IN A MORE TEMPARIAN STAGE), AT THE TIME OF DETECTING A GENETIC VARIANT DESCRIBED HEREIN. IN SOME MODES, THE GENETIC VARIANTE IS AN ELIMINATION / INSERTION POLYMORPHISM (DIP) OF THE TOMM40 GEN.-
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CR20130199A CR20130199A (en) | 2013-05-02 | 2013-05-02 | METHOD OF IDENTIFICATION OF RISK FACTORS OF THE DISEASE |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CR20130199A CR20130199A (en) | 2013-05-02 | 2013-05-02 | METHOD OF IDENTIFICATION OF RISK FACTORS OF THE DISEASE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20130199A true CR20130199A (en) | 2013-10-23 |
Family
ID=51359533
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20130199A CR20130199A (en) | 2013-05-02 | 2013-05-02 | METHOD OF IDENTIFICATION OF RISK FACTORS OF THE DISEASE |
Country Status (1)
| Country | Link |
|---|---|
| CR (1) | CR20130199A (en) |
-
2013
- 2013-05-02 CR CR20130199A patent/CR20130199A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2200011I1 (en) | Compositions and methods for inhibiting the expression of the HAO1 (hydroxy acid oxidase-1 (glycolate oxidase)) gene | |
| CL2015002127A1 (en) | Systems and methods for clinical decision support. | |
| MX372723B (en) | METHODS FOR LABELING A DEUTERATED OR NON-DEUTERATED MOLECULE AND PHARMACEUTICAL FORMULATIONS FOR TREATMENT. | |
| MX2016011538A (en) | Antisense nucleic acid. | |
| MX2018002955A (en) | Antisense nucleic acid. | |
| EP3484994A4 (en) | CRISPR-CAS-SYSTEM FOR AN ALGENE CELL | |
| CO2017013065A2 (en) | Diaciglycerol acyltransferase 2 modulators (dgat2) | |
| CL2018000596A1 (en) | New bicyclic compounds as atx inhibitors | |
| PE20180260A1 (en) | METHODS AND KITS TO TREAT DEPRESSION | |
| MX392552B (en) | METHODS FOR ISOLATING MICROVESICLES. | |
| BR112018001853A2 (en) | methods for treating a disorder and for improving the treatment of a disorder | |
| MX2017005820A (en) | MICROAGUJAS ARRANGEMENTS FOR APPLICATIONS IN CANCER THERAPIES. | |
| MX2016004865A (en) | METHOD AND DEVICE FOR ANALYZING SOCIAL RELATIONSHIP. | |
| BR112018069303A2 (en) | method for treating an infection | |
| MX2015012176A (en) | Methods of using zscan4 for rejuvenating human cells. | |
| BR112017009554A2 (en) | inspection device for use in a fluid container and inspection device for use in a fluid | |
| MX2016013877A (en) | Compositions and methods for enhancing and/or predicting dna amplification. | |
| EP3498836A4 (en) | MANUFACTURING PROCESS FOR L-AMINO ACID | |
| CL2014002975A1 (en) | In vitro method for the diagnosis and surveillance of cancer, which comprises determining the ratio between treg cells and another group of t cells, selected from th17, th1 and / or th2. | |
| CL2016002754A1 (en) | Treatment device and treatment procedure for pickling and phosphating metal parts | |
| MX2017007000A (en) | Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same. | |
| MX2016012248A (en) | Compositions for the treatment of autodigestion. | |
| BR112017013256A2 (en) | method of analysis, disk-shaped sample holder and application of a sample holder | |
| BR112016028909A2 (en) | method and device for tissue closure | |
| UY34189A (en) | FUNGICIDE BLENDS THAT INCLUDE ISOXAZOL AND OTHER ACTIVE INGREDIENT. |